Carl Zeiss Meditec Closes Financial Year on a High and Consistently Pursues its Growth Course
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG /
Carl Zeiss Meditec Closes Financial Year on a High and Consistently Pursues its
Growth Course
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Revenue increases by 12.1 percent in FY 2010/2011 - EBIT margin climbs to 13.6
percent - Earnings per share rise disproportionately by 20.6 percent
JENA, 8 December 2011
The medical technology provider Carl Zeiss Meditec has successfully closed its
financial year (ending 30 September 2011). All regions and strategic business
units (SBU) contributed to the result.
"Despite the adverse general economic situation we have been able to continue
our growth course and even exceed our expectations," says Dr Ludwin Monz,
President and CEO of Carl Zeiss Meditec AG.
The Company generated consolidated revenue of EUR 758.8 million in financial
year 2010/2011, compared to EUR 676.7 million the previous year. This
corresponds to an increase of 12,1 percent. Earnings (before interest and taxes)
increased disproportionately by 19.4 percent to EUR 103.6 million (previous
year: EUR 86.7 million). "Although we continued to invest in new products, and
to establish and expand our sales and service structures, we have succeeded in
increasing profitability. This is not least because we managed to further
improve the manufacturing cost position," explains Dr Ludwin Monz. The EBIT
margin increased to 13.6 percent (previous year: 12.8 percent) and earnings per
share could be raised to EUR 0.82 (previous year: EUR 0.68). "Our corporate
program MEGA is bearing the first fruits and the results achieved are an
endorsement of the growth- and profitability-oriented path we decided to take,"
he adds. The Supervisory Board and Management Board therefore propose to the
Annual General Meeting a dividend of EUR 0.30 per share for financial year
2010/2011.
Revenue by business unit
The Microsurgery SBU achieved a growth of 20.0 percent - well above the market
development rate. The SBU Surgical Ophthalmology with its innovative intraocular
lenses (IOL) grew by 6.0 percent and the SBU Ophthalmic Systems contributed with
a growth of 7.2 percent.
The pleasing rate of growth was driven in particular by new products. In the
reporting year Carl Zeiss Meditec invested 11.1 percent of sales in innovations
and solutions. 14.5 percent of the workforce was engaged in research and
development, and the Company acquired patents at an average rate of one per
week.
Revenue by region
Despite the worsening government debt crisis in the Euro region, the EMEA region
(Europe, Middle East, Africa) posted a 7.9 percent increase in revenue. The
solid performance in the USA was accompanied by growth in Latin American
countries, resulting in overall growth of 11.5 percent. Similarly, the Company
recorded a two-digit growth rate of 18.1 percent in the Asian/Pacific region.
This was mainly attributable to the growing Indian and Chinese markets, but
despite the serious natural and nuclear disasters early in the year Japan also
continued to develop positively. The Asian/Pacific region with vast development
potential remains the strongest region in terms of growth.
Outlook
Against a background of volatile constraints, a forecast for the current
business year is difficult. Demographic trends will continue to be beneficial to
the company's business. "With our broad business base and global presence we are
comparatively resistant to economic upheavals. In addition, our well-established
sales and service organisations will enable us to seize a sizeable share of
growth in emerging economies in Asia and South America. At the same time we will
be concentrating on a continued increase in profitability," explains Dr Monz. By
2015 the company is striving for an EBIT margin of 15 percent.
Future growth will be promoted and supported by the corporate program MEGA 2015
(Meditec Excellence and Growth Agenda) for facilitating the implementation of
the corporate strategy and a consistent focus on the success factors innovation,
customer orientation, new markets, employees and processes. "With our products
and solutions for ophthalmology and microsurgery we aim to contribute to medical
progress", concludes Dr Ludwin Monz.
Revenue by strategic business unit
+----------------------+------------------+------------------+-----------------+
|Figures in |Financial year |Financial year |Change from |
|EUR '000 |2009/2010 |2010/2011 |previous year |
+----------------------+------------------+------------------+-----------------+
|Ophthalmic Systems |322,711 |345,972 |7.2% |
| | | | |
| | | | |
+----------------------+------------------+------------------+-----------------+
|Surgical Ophthalmology|85,575 |90,676 |6.0% |
+----------------------+------------------+------------------+-----------------+
|Microsurgery |268,396 |322,145 |20.0% |
+----------------------+------------------+------------------+-----------------+
Revenue by region
+-------------------+-------------------+-------------------+------------------+
|Figures in |Financial year |Financial year |Change from |
|EUR '000 |2009/2010 |2010/2011 |previous year |
+-------------------+-------------------+-------------------+------------------+
|EMEA |242,632 |261,786 |7.9% |
+-------------------+-------------------+-------------------+------------------+
|Americas |238,450 |265,964 |11.5% |
+-------------------+-------------------+-------------------+------------------+
|Asia/Pacific region|195,600 |231,043 |18.1% |
+-------------------+-------------------+-------------------+------------------+
Press contact
Petra Rettenmaier, Director Corporate Communications, Carl Zeiss Meditec AG,
Phone. 03641 220-331, E-Mail: press(at)meditec.zeiss.com
Contact for investors
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec AG
Phone. 03641 220-106, E-Mail: investors(at)meditec.zeiss.com
www.meditec.zeiss.com/press
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1569934]
Unternehmensinformation / Kurzprofil:
Datum: 08.12.2011 - 06:57 Uhr
Sprache: Deutsch
News-ID 94943
Anzahl Zeichen: 7695
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec Closes Financial Year on a High and Consistently Pursues its Growth Course"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
